Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
Esperion (NASDAQ: ESPR) reported strong financial results for Q4 and FY 2024, with total revenue growing 186% year-over-year to $332.3 million. U.S. net product revenue increased 48% to $115.7 million for FY24, while Q4 total revenue rose 114% to $69.1 million.
The company's Q4 retail prescription equivalents grew 45% Y/Y and 12% Q/Q, with expanded prescriber base now totaling over 25,000 healthcare practitioners. Esperion announced development of triple combination products with bempedoic acid in the U.S., potentially offering LDL-C lowering exceeding 60%.
Key highlights include:
- Products now approved in 39 countries globally
- Expanded payer access covering 173 million lives
- Otsuka submitted New Drug Application in Japan
- Net loss improved to $51.7 million in FY24 from $209.2 million in FY23
- Cash position strengthened to $144.8 million as of December 31, 2024
Esperion Therapeutics (NASDAQ: ESPR) has entered into a license and distribution agreement with CSL Seqirus for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Australia and New Zealand. The deal includes:
- An upfront payment and milestone payments up to $5 million
- A profitable transfer price for Esperion on product supply
- CSL Seqirus handling commercialization, regulatory approval, and marketing
The partnership targets significant markets where cardiovascular disease affects 1.2 million people in Australia and 175,000 adults in New Zealand. Both medications are indicated to reduce myocardial infarction risk and lower LDL-C in adults with primary hyperlipidemia who cannot take recommended statin therapy.
Esperion (NASDAQ: ESPR) has announced it will report fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before market opens. Management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
The company is a commercial stage biopharmaceutical firm that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) with allosteric mechanisms.
Esperion (NASDAQ: ESPR) has granted 58,300 restricted stock units (RSUs) to ten new employees under its 2017 Inducement Equity Incentive Plan on February 11, 2025. The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments, subject to continued employment.
The grants are specifically designed as employment inducements for new hires who were not previously associated with Esperion, in compliance with NASDAQ Listing Rule 5635(c)(4). Esperion is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.
Esperion (NASDAQ: ESPR) has announced a virtual key opinion leader (KOL) event scheduled for January 22, 2025, at 11:30 a.m. ET. The event will focus on the real-world use of NEXLETOL® and NEXLIZET®, featuring discussions led by LeAnne Bloedon, VP of Clinical Development, and Dr. Patrick Moriarty from The University of Kansas Medical Center.
The webinar will address unmet needs in LDL-Cholesterol management for cardiovascular disease prevention. Esperion's medications are FDA-approved, oral, once-daily, non-statin medicines supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.
The company is also advancing its next-generation program developing ATP citrate lyase inhibitors (ACLYi), focusing on creating highly potent and specific inhibitors with allosteric mechanisms. The event will be accessible via webcast on Esperion's website, with replay available for approximately 90 days.
Esperion (NASDAQ: ESPR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Wednesday, January 15, 2025, at 3:45 p.m. PT. The presentation will be accessible via webcast through Esperion's investor and media section, with replay available for approximately 90 days.
Esperion is a commercial stage biopharmaceutical company that has developed the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. These medications are backed by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new structural and functional insights for developing highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.
Esperion (NASDAQ: ESPR) has completed significant refinancing transactions to strengthen its balance sheet. The company secured a $150 million senior secured term loan facility led by Athyrium Capital Management and HealthCare Royalty, along with issuing $100 million in new convertible notes. These funds will be used to repay $210 million of existing $265 million convertible debt, with $40 million allocated as operating cash.
The new loan bears interest at 9.75% for cash payments or 11.75% if paid in-kind. The new convertible notes mature on June 15, 2030, with a 5.75% annual interest rate and an initial conversion price of $3.06 per share. This restructuring affects 80% of Esperion's existing debt, extending maturity dates by five years or more.
Esperion (NASDAQ: ESPR) has announced a $210 million convertible debt financing through privately negotiated agreements. The company will issue $100 million of 5.75% Convertible Senior Subordinated Notes due 2030, consisting of $57.5 million in new notes plus $153.4 million in cash to exchange $210.1 million of existing 2025 Notes, and $42.5 million in new notes for cash.
The new notes will mature on June 15, 2030, with a 5.75% annual interest rate paid semi-annually. The initial conversion rate is 326.7974 shares per $1,000 principal amount, representing a conversion price of approximately $3.06 per share. The Exchange Transactions will be partially funded through a new $150 Million Senior Secured Term Loan with Athyrium Capital Management.
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will receive exclusive commercialization rights in Israel, Gaza, and West Bank. Esperion will receive a one-time upfront cash payment within 30 days of signing, plus an additional payment following marketing approval and inclusion in the National Healthcare Reimbursement Basket. The partnership aims to address cardiovascular disease, which remains a leading cause of death globally.
Esperion (NASDAQ: ESPR) has submitted New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily oral non-statin medications for reducing LDL cholesterol and cardiovascular risk. These treatments target adults unable to take recommended statin therapy, with either established cardiovascular disease or high risk for CVD events. According to Canadian health data, approximately 2.6 million Canadian adults live with diagnosed heart disease, with 14 adults dying every hour from the condition.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
